Office Visits to Monitor Stimulant Medication Safety and Efficacy: Recommended Care.

Autor: Zima BT; UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA. Electronic address: bzima@mednet.ucla.edu., Norquist GS; Emory University, Atlanta, GA., Altchuler SI; Mayo Clinic, Rochester, MN., Behrens J; Envision ADHD, Milwaukee, WI., Iles-Shih MD; Harborview Medical Center, University of Washington, Seattle., Ng YKW; Division of Child and Adolescent Psychiatry at Columbia University Medical Center and New York-Presbyterian/Morgan Stanley Children's Hospital, New York., Schaepper MA; Loma Linda University Medical Center, Loma Linda, CA.
Jazyk: angličtina
Zdroj: Journal of the American Academy of Child and Adolescent Psychiatry [J Am Acad Child Adolesc Psychiatry] 2018 Jun; Vol. 57 (6), pp. 438-439.
DOI: 10.1016/j.jaac.2018.02.015
Abstrakt: The clinical guidance based on the research article, "Specific Components of Pediatricians' Medication-Related Care Predict Attention-Deficit/Hyperactivity Disorder Improvement," published in the June 2017 issue, 1 might be premature. The authors, Epstein et al., suggest that "Physicians do not need to necessarily rely on office visits to monitor medication response and side effects in the week(s) after initially prescribing medication, but instead could use phone calls or email correspondence to check in with the family" (p. 489). However, this advice has the potential to be misinterpreted that phone or email contact is acceptable clinical practice to monitor stimulant medication safety and efficacy, especially during the maintenance phase. It also could be erroneously interpreted that phone or email contact is sufficient for follow-up care for children receiving medication treatment for attention-deficit/hyperactivity disorder (ADHD) for national quality measures.
(Copyright © 2018 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE